Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma

被引：15

作者：

Evans, Robert P. ^{[1
]}

Dueck, Greg ^{[1
]}

Sidhu, Roger ^{[1
]}

Ghosh, Sunita ^{[1
]}

Toman, Inka ^{[1
]}

Loree, Jonathan ^{[1
]}

Bahlis, Nizar ^{[1
]}

Klimowicz, Alexander C. ^{[1
]}

Fung, Joyce ^{[1
]}

Jung, Michelle ^{[1
]}

Lai, Raymond ^{[1
]}

Pilarski, Linda M. ^{[1
]}

Belch, Andrew R. ^{[1
]}

Reiman, Tony ^{[1
]}

机构：

[1] St Johns Hosp, Dept Oncol, St John, NB E2L 4L2, Canada

来源：

LEUKEMIA RESEARCH | 2011年 / 35卷 / 12期

关键词：

Polo-like kinase 1; PLK1; Multiple myeloma; Novel therapeutics; RISK STRATIFICATION; DIAGNOSIS; CELLS; PLK;

D O I：

10.1016/j.leukres.2011.07.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The amplified myeloma centrosome has been identified as a therapeutic target. The present study explored the expression and prognostic significance of the centrosome-associated protein PLK1 in myeloma and the effect of BI 2536, a potent and selective inhibitor of PLK1, on myeloma cells. High plasma cell expression of PLK1 protein in myeloma patient bone marrow biopsies is an independent adverse prognostic factor (HR = 2.3, p = 0.003 unadjusted; HR = 1.9, p = 0.03 in multivariable model). BI 2536 inhibits myeloma cell lines at nanomolar concentrations, and is therapeutic for xenografts in NOD/SCID mice. PLK1 inhibition is a potential new strategy for the treatment of multiple myeloma. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：1637 / 1643

页数：7

共 50 条

[1] Prognostic significance of polo-like kinase expression in esophageal carcinoma
Tokumitsu, Y
Mori, M
Tanaka, S
Akazawa, K
Nakano, S
Niho, Y
INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (04) : 687 - 692
[2] Small-molecule inhibitors for targeting polo-like kinase 1
Kolosenko, Iryna
Palm-Apergi, Caroline
FUTURE MEDICINAL CHEMISTRY, 2020, 12 (16) : 1457 - 1460
[3] Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer
Georg Wolf
Robert Elez
Andreas Doermer
Uwe Holtrich
Hanns Ackermann
Hans Jochen Stutte
Hans-Michael Altmannsberger
Helga Rübsamen-Waigmann
Klaus Strebhardt
Oncogene, 1997, 14 : 543 - 549
[4] Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer
Wolf, G
Elez, R
Doermer, A
Holtrich, U
Ackermann, H
Stutte, HJ
Altmannsberger, HM
RubsamenWaigmann, H
Strebhardt, K
ONCOGENE, 1997, 14 (05) : 543 - 549
[5] Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer
Lashen, Ayat G.
Toss, Michael S.
Wootton, Louisa
Green, Andrew R. R.
Mongan, Nigel P.
Madhusudan, Srinivasan
Rakha, Emad
HISTOPATHOLOGY, 2023, 83 (03) : 414 - 425
[6] Polo-like Kinase 1 Inhibition as a New Therapeutic Modality in Therapy of Cholangiocarcinoma
Thrum, Stephan
Lorenz, Jana
Moessner, Joachim
Wiedmann, Marcus
ANTICANCER RESEARCH, 2011, 31 (10) : 3289 - 3299
[7] Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
Pezuk, Julia Alejandra
Brassesco, Maria Sol
Manzini Ramos, Priscila Maria
Scrideli, Carlos Alberto
Tone, Luiz Gonzaga
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (09) : 1278 - 1291
[8] Polo-like kinase 1 expression is a prognostic factor in human colon cancer
Weichert, Wilko
Kristiansen, Glen
Schmidt, Mathias
Gekeler, Volker
Noske, Aurelia
Niesporek, Silvia
Dietel, Manfred
Denkert, Carsten
WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (36) : 5644 - 5650
[9] Structural basis for the inhibition of Polo-like kinase 1
Xu, Jun
Shen, Chen
Wang, Tao
Quan, Junmin
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2013, 20 (09) : 1047 - +
[10] Structural basis for the inhibition of Polo-like kinase 1
Jun Xu
Chen Shen
Tao Wang
Junmin Quan
Nature Structural & Molecular Biology, 2013, 20 : 1047 - 1053

← 1 2 3 4 5 →